Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Induct – Private Placement towards NPP Capital AS

Induct has completed a Private Placement of NOK 3 million through the subscription of 750,000 new shares at a subscription price of NOK 4.00 per share. Payment will take place 5 May 2020. The shares were subscribed by NPP Capital AS, a company 100% owned by Alf Martin Johansen, who is Induct's CEO. The new shares to be issued under the Private Placement will be listed on Merkur Market as soon as practically possible after registration of the share capital increase in the Norwegian Register of Business Enterprises, expected on or about 20 May 2020. NPP Capital AS' total holding

BioStock: Synact Pharma on expansion into Covid-19

A serious consequence of the Covid-19 infection is severe pneumonia, which can lead to acute respiratory distress syndrome (ARDS) and the subsequent need for respiratory treatment. Earlier this week, SynAct Pharma announced that it intends to position its clinical anti-inflammatory drug candidate AP1189 as an adjunctive therapy in hospitalised patients with Covid-19 infection in order to prevent ARDS. BioStock contacted the company’s CEO Jeppe Øvlesen for a comment.Read the full interview with Synact Pharma's CEO Jeppe Øvlesen at biostock.se: https://www.biostock.se/en/synact-pharma-on-

Cereno Scientific strengthens its clinical expertise, recruits top expert as Scientific Advisor

Cereno Scientific today announced that the company is strengthening its clinical expertise by recruiting Dr. Raymond L. Benza, Professor of Medicine and Director, Division of Cardiovascular Medicine, at the Ohio State University Wexner Medical Center in Columbus, USA, as Scientific Advisor to the company.Earlier this March, Cereno Scientific was granted Orphan Drug Designation, by the U.S. Food and Drug Administration (FDA) for the company’s lead compound CS1 to treat the rare disease Pulmonary Arterial Hypertension (PAH), which is a form of high blood pressure in the lungs where the

Polygiene launches ViralOff, a Polygiene technology

The application for the ViralOff® antiviral technology will range from medical equipment and wear, like scrubs and uniforms to consumer products where antiviral properties make sense, like face masks, gloves and other crucial products. The new product will be available immediately in most markets*.   Back in 2004, the SARS epidemic was raging. Demand for antiviral and antibacterial treatments was soaring. As smart scientists and technicians at the Swedish chemical company Perstorp came up with new solutions, a new company was spun off – Polygiene. But memory of SARS waned, and we

K-Fastigheter's 2019 Annual report in Swedish now available

K-Fast Holding AB (“K-Fastigheter”) today published the 2019 Annual report in Swedish, on its website, www.k-fastigheter.se.The Swedish version of the 2019 Annual report is available on www.k-fastigheter.se/for-investerare/finansiella-rapporter/. A printed copy can be ordered via ir@k-fastigheter.se. The English version will be available in the week commencing 20 April 2020. For further information, please contact:Anders Antonsson, IR Manager, e-mail: anders.antonsson@k-fastigheter.se, telephone: +46 709 994 970 This information is such information as K-Fast Holding AB is obliged to

2cureX establish clinical partnership with Skåne University Hospital, Sweden

Copenhagen — April 2, 2020 — 2cureX AB (“2cureX”, NASDAQ: 2CUREX) announced today that the company’s international network of collaborative hospitals within colorectal cancer has gained yet another member, Skåne University Hospital.The health service and its hospitals are struggling every single day to mitigate the consequences of the Covid-19 pandemic. At the same time, there is an awareness that everyday life is waiting on the other side of the pandemic, and that cancer patients in particular need ongoing treatment improvements. 2cureX has a well-established collaboration with a number

Alfa Laval signs offshore predictive maintenance agreement

Alfa Laval – a world leader in heat transfer, centrifugal separation and fluid handling – has signed a maintenance agreement with Aker BP, an oil exploration and development company, for Alfa Laval’s Framo seawater lift pumps to off-shore platforms in the North Sea. The order value is directly linked to facility uptime. The agreement has a duration of six years, with an option for an additional six yearsThe maintenance contract is a continuation of a pilot project that started second half of 2018 between Alfa Laval’s Business Unit Pumping Systems, Aker BP and the global AI software company

NOTICE OF ANNUAL GENERAL MEETING IN asarina pharma AB (publ)

The shareholders of Asarina Pharma AB (publ) (the “Company”) are hereby summoned to attend the Annual General Meeting (“AGM”) on 5 May 2020, at 10.00 CEST at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 09.30 CEST and will stop when the meeting starts. NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail.The Company is closely monitoring the development of covid-19, the corona virus, and will revert with more information closer to the AGM if it is deemed

Postponement of DNB’s annual general meeting

DNB ASA normally holds its Annual General Meeting in April each year. Due to the extraordinary situation caused by the spread of the corona virus and the authorities' restrictions on mass gatherings, the Board of Directors of DNB ASA has decided to postpone the general meeting. In addition, the Board refers to Oslo municipality’s ban on gatherings in the regulations relating to the prevention of the spread of the corona virus in the municipality of Oslo, adopted by the Oslo City Council on March 27[th], 2020. A new Annual General Meeting will be called within the ordinary deadline

Endomines’ Friday mine project in Idaho, Successfully Commissions Orogrande Processing Facility

Endomines AB, Stock Exchange Release 2 April 2020 at 08:30 CESTEndomines AB (the “Company” or “Endomines”) is pleased to announce that it continues to make significant progress at its Orogrande Processing Facility (“OPF”) and the Friday Underground Mine in Idaho County, Idaho, USA. At the mine, ore production has proceeded as scheduled, and preproduction development has advanced more rapidly than expected. At the present time, development has been completed for the first two stoping areas with enough mineralized material to supply a full-time feed to the mill for the next 6 months.

Tele2 IoT Helping 9Solutions Provide Nurse Call Systems to Front Line Healthcare Workers

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) Tele2 IoT is supporting Finland’s 9Solutions to ensure the functionality of healthcare services in exceptional circumstances. Tele2 IoT will help 9Solutions to bring its Nurse Call Lite solution to the healthcare community.Tele2 IoT is proud to be a part of helping 9Solutions to bring its Nurse Call Lite solution to the healthcare community. Tele2 IoT will continue to support them in their efforts to enable medical personnel to work in safe and secure environments.9Solutions has responded to the fight against Covid-19

Vitrolife postpones the Annual General Meeting

Due to the great uncertainty caused by the extensive dissemination of covid-19, Vitrolife's Board of Directors has decided to postpone the Annual General Meeting to a later date.The Annual General Meeting was originally scheduled to be held on April 28, 2020 in Gothenburg. Vitrolife will return with a notice to the AGM no later than four weeks before the new date. The meeting will be held in accordance with current legislation. Gothenburg, SwedenApril 2, 2020VITROLIFE AB (publ)

Enzymatica - publication of the Annual Report 2019

Enzymatica announces today that the annual report 2019 is available on the company's web site www.enzymatica.se. The annual report is produced in Swedish. A brief English version of the annual report is available on the English version of the website.https://www.enzymatica.se/investerare/finansiella-rapporter/ or https://www.enzymatica.se/en/investors/financial-reports/For more information, please contact: Fredrik Lindberg, CEO Enzymatica ABPhone: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com Carl-Johan Wachtmeister, Communication manager Enzymatica ABPhone: +46 (0)

Issue and repurchase of shares of series C for securing Karnov Group’s obligations under its share-related incentive program

The Board of Directors of Karnov AB (publ) has today resolved to issue 378,837 shares of series C and to immediately repurchase all such shares of series C. The issue and repurchase of shares of series C are carried out in order to secure the company’s obligations under its share-related incentive program LTIP 2019 for employees.The Board of Directors resolutions were made by virtue of the authorisations by the extraordinary general meeting of the company on 10 April 2019. The shares of series C were subscribed and paid for, and immediately repurchased from, Nordea Bank Abp. Both the

Veoneer and Volvo Cars to split joint venture to pursue separate ADAS and autonomous driving strategies

Stockholm, Sweden, April 2, 2020: The automotive technology company Veoneer, Inc. (NYSE: VNE and SSE: VNE SDB), have following a strategic review, entered into a non-binding agreement with Volvo Cars to split their 50/50 joint venture Zenuity.The parties have agreed in principle that Veoneer will integrate and operate the current Zenuity business focused on the development and commercialization of advanced driver assistance system (ADAS) software for collaborative driving. Volvo Cars will setup a new stand-alone company to take over Zenuity’s current development and commercialization of

Electrolux highlights lower emissions and introduces new framework in 2019 Sustainability Report

Electrolux, a sustainability leader in the appliance industry, reports a 75% reduction in CO2 emissions from its operations since 2005. To reflect the Group’s new commitment to become climate neutral across the supply chain by 2050, and its increasingly holistic approach to sustainability, the overall sustainability framework has also been updated.The reduction of direct and indirect environmental impact is increasingly an important focus area for Electrolux. The 2019 Sustainability Report, released today, shows the company’s progress towards its targets in the nine key areas outlined in

AFRY to design double-track railway development between Ängelholm and Maria station

The turnkey contract for the double-track railway development on the Swedish train line Västkustbanan, between Ängelholm and Maria station in Helsingborg has been awarded to Skanska by the Swedish Transport Administration. AFRY will produce the construction documents, on behalf of Skanska and the railway contractor Strukton.The Ängelholm–Maria station in Helsingborg stretch is part of the Västkustbanan West Coast train line running between Gothenburg and Lund/Malmö. In recent years, the train line has undergone a phased expansion to double tracks, and now it is time for the Ängelholm-Maria

Bravida Sweden acquires refrigeration technology company in Bohuslän

Bravida acquires Kylteknik Bohuslän AB in Stenungsund, thereby strengthening its position in refrigeration technology in western Sweden.Since 1997, Kylteknik Bohuslän AB has delivered servicing and installation of refrigeration facilities to shops, shipping, industries, catering facilities and more. The company has a turnover of around SEK 21 million and has 13 employees, including nine refrigeration technicians. Stefan Sandström, Business Area Manager Cooling at Bravida, Division Riks, explains the background to the acquisition: “Bravida is working to become a leading partner for

AstraZeneca divestment of Movantik to RedHill Biopharma completed

2 April 2020 07:00 BST AstraZeneca divestment of Movantik to RedHill Biopharma completed AstraZeneca has completed the previously communicated agreement  to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo,

H&M Group Sustainability Performance Report 2019

Today, the H&M Group Sustainability Performance Report 2019 is released. It highlights progress towards the company’s vision to lead the change towards circular and climate positive fashion while being a fair and equal company.“I am proud of all the progress we did in 2019. Looking ahead, not only our industry will continue changing rapidly, but also the world as a whole. This 2020 has started with a challenge we never saw before with the spread of COVID-19 affecting the whole world, companies and societies. I am confident that the long-term vision we always had, and will continue having,

BioArctic publishes the Annual Report for 2019

Stockholm April 2, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for the 2019 has been published in Swedish. The Annual Report, which is attached in Swedish, can also be downloaded from the company’s Swedish website, www.bioarctic.se (Investerare/Finansiella rapporter). An English translation of the Annual report is estimated to be available on the webpage on April 17, 2020. For further information, please contact: Jan Mattsson, CFO, telephone + 46 (0) 70 352 27 72 This information is information that BioArctic AB (publ) is obliged

Oncopeptides strengthens its corporate communications function by appointing Rolf Gulliksen as Global Head of Corporate Communications

STOCKHOLM — April 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate communications. Rolf has 30 years of experience from senior corporate communications roles in the life science industry and consultancy.Prior to joining Oncopeptides, he served as head of corporate communications at Hansa Biopharma. He will be a member of Oncopeptides’ Management Team and will start today. “Communication will be a critical function to support our growing business and presence in key markets and pave the way for our first

Camurus announces strong first quarter demand for Buvidal®

· Large increase in the number of patients treated with weekly and monthly Buvidal[®] for opioid dependence · Camurus reiterates its 2020 outlook, with sales and total revenues expected to reach the higher end of previous guidance Lund, Sweden — 2 April 2020 — Camurus announced today continued strong revenue growth driven by increasing demand for weekly and monthly Buvidal for the treatment of opioid dependence in EU and Australia. The company’s 2020 outlook was reiterated with expected product sales and total revenues at the higher end of previously communicated guidance*. “We see

There are no items matching the current filter
There are no more items matching the current filter
Back to top